Please login to the form below
psilocybin
This page shows the latest psilocybin news and features for those working in and with pharma, biotech and healthcare.
Low-dose LSD looks safe for Alzheimer’s patients, but will it work?
Eleusis’ trial comes after the non-profit Usona Institute launched a phase 2 trial of psilocybin – found in ‘magic mushrooms’ – as a treatment for major depressive disorder.
Latest news
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
War on drugs: the use of controlled substances in medicine
Psilocybin (aka magic mushrooms) has shown promise in treating a variety of difficult-to-treat health conditions such as depression and cancer-related anxiety.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
